中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2012年
22期
53-55
,共3页
鼻咽癌%顺铂%同期放化疗
鼻嚥癌%順鉑%同期放化療
비인암%순박%동기방화료
Nasopharyngeal neoplasm%Cisplain%Concurrent radiochemotherapy
目的 观察同步放化疗治疗局部晚期鼻咽癌的临床疗效及不良反应.方法 2007年2月至2009年2月,对河南省肿瘤医院收治行同步放化疗的38例初治中晚期鼻咽癌患者的疗效进行回顾性分析,并与同时期行单纯放疗的38例患者的结果相比较.同步组接受采用小剂量DDP(每周40 mg/m2,共7～8周)加普通放疗,单放组接受单纯普通放疗.结果 同步组和单放组的完全缓解率(CR)分别为78.9％(30/38)和71.0％(27/38),差异无统计学意义(P＞0.05).3年局部控制率同步组为73.7％(28/38),单放组为50.0％(19/38),二者比较差异有统计学意义(P＜0.05).3年总生存率同步组为68.4％(26/38),单放组为44.7％ (17/38),二者比较差异有统计学意义(P＜0.05).3年无远处转移生存率同步组为63.2％ (24/38),单放组为39.5％(15/38),二者比较差异有统计学意义(P＜0.05).同步组Ⅲ/Ⅳ级白细胞下降及恶心、呕吐的发生率明显高于单放组(P＜0.05).结论 同步调强放化疗对局部晚期鼻咽癌疗效较好,且不良反应可耐受.
目的 觀察同步放化療治療跼部晚期鼻嚥癌的臨床療效及不良反應.方法 2007年2月至2009年2月,對河南省腫瘤醫院收治行同步放化療的38例初治中晚期鼻嚥癌患者的療效進行迴顧性分析,併與同時期行單純放療的38例患者的結果相比較.同步組接受採用小劑量DDP(每週40 mg/m2,共7～8週)加普通放療,單放組接受單純普通放療.結果 同步組和單放組的完全緩解率(CR)分彆為78.9％(30/38)和71.0％(27/38),差異無統計學意義(P＞0.05).3年跼部控製率同步組為73.7％(28/38),單放組為50.0％(19/38),二者比較差異有統計學意義(P＜0.05).3年總生存率同步組為68.4％(26/38),單放組為44.7％ (17/38),二者比較差異有統計學意義(P＜0.05).3年無遠處轉移生存率同步組為63.2％ (24/38),單放組為39.5％(15/38),二者比較差異有統計學意義(P＜0.05).同步組Ⅲ/Ⅳ級白細胞下降及噁心、嘔吐的髮生率明顯高于單放組(P＜0.05).結論 同步調彊放化療對跼部晚期鼻嚥癌療效較好,且不良反應可耐受.
목적 관찰동보방화료치료국부만기비인암적림상료효급불량반응.방법 2007년2월지2009년2월,대하남성종류의원수치행동보방화료적38례초치중만기비인암환자적료효진행회고성분석,병여동시기행단순방료적38례환자적결과상비교.동보조접수채용소제량DDP(매주40 mg/m2,공7～8주)가보통방료,단방조접수단순보통방료.결과 동보조화단방조적완전완해솔(CR)분별위78.9％(30/38)화71.0％(27/38),차이무통계학의의(P＞0.05).3년국부공제솔동보조위73.7％(28/38),단방조위50.0％(19/38),이자비교차이유통계학의의(P＜0.05).3년총생존솔동보조위68.4％(26/38),단방조위44.7％ (17/38),이자비교차이유통계학의의(P＜0.05).3년무원처전이생존솔동보조위63.2％ (24/38),단방조위39.5％(15/38),이자비교차이유통계학의의(P＜0.05).동보조Ⅲ/Ⅳ급백세포하강급악심、구토적발생솔명현고우단방조(P＜0.05).결론 동보조강방화료대국부만기비인암료효교호,차불량반응가내수.
Objective To investigate the clinical effect and toxicity of concurrent radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.Methods From February 2007 to February 2009,the retrospective effectiveness and adverse reactions analysis of 38 cases of locally advanced nasopharyngeal carcinoma accepted concurrent chemoradiotherapy (CCRT group) and 38 cases of locally advanced nasopharyngeal carcinoma accepted radiotherapy alone (RT group).Patients in CCRT group were received radiotherapy combined chemotherapy with DDP [40 mg/(m2/week),7-8 weeks],and patients in RT group were received radiotherapy alone.Results Comparing the CCRT group and RT group,the complete remission rate (CR) was 78.9％ and 71.0％,respectively,P ＞0.05 ; The 3-year local control rate in CCRT group and in RT group was 73.7％ (28/38) and 50.0％(19/38),respectively,P ＜ 0.05.3-year overall survival rate was 68.4％ and 44.7％,respectively,P ＜ 0.05; 3-year distant metastasis-free survival rate was 63.2％ and 39.5％,respectively,P ＜0.05.The incidence of gradeⅢ and Ⅳ leucopenia and nausea and vomiting in CCRT group was significantly higher than that in RT group (P ＜ 0.05).Conclusions Concurrent RT and chemotherapy for locally advanced nasopharyngeal carcinoma is effective and tolerable.
